Proactive Investors - Run By Investors For Investors

Zelda Therapeutics reflects on busy December half

The company’s cash at bank was $4.41 million at the end of the 2018 calendar year.
Proactive interview with Dr Richard Hopkins
Zelda plans to value add all the way from clinical trials to the market

Zelda Therapeutics Ltd (ASX:ZLD) has made significant progress in its strategy to grow its business in the December half of 2018.

The company’s focus remains on the development of novel cannabinoid-based therapies for a range of diseases.

READ: Zelda Therapeutics on track to report on multiple clinical trials

Zelda is undertaking a human clinical trial program focused on insomnia, autism and opioid reduction with activities in Australia and the US.

Pre-clinical research activities include programs examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

Zelda also formed a strategic partnership with European medicinal cannabis group HAPA Medical BV, to access HAPA’s EU-GMP grade manufacturing capabilities and accessing its German distribution network

READ: Zelda Therapeutics links up with International Cannabis and Cannabinoids Institute

Proactive spoke to Zelda’s managing director Dr Richard Hopkins about their vertically integrated strategy in December 2018.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full ZLD profile View Profile

Zelda Therapeutics Ltd Timeline

Related Articles

August 28 2018
Tidal Royalty provides capital to help grow licenced US cannabis firms in exchange for receiving a percentage of future top-line revenues.
cannabis plant
May 06 2019
The cannabis company invests in income-producing property and provides financing solutions and capital investment to service the blossoming cannabis industry
cannabis facility
January 24 2019
The company is breaking into the large and lucrative market in the golden state

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use